Navigation Links
Urocidin™ Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences
Date:2/17/2011

CHADDS FORD, Pa. and BELLEVILLE, Ontario, Feb. 17, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) and Bioniche Life Sciences Inc. (TSX and ASX: BNC) today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348. The results to be presented have been generated from an ongoing Phase III registration trial with Urocidin™ in the treatment of non-muscle-invasive bladder cancer (NMIBC) that is refractory to current first-line therapy (Bacillus Calmette-Guerin, known as BCG).

The first abstract and poster summaries of such results will be made available during the Annual Congress of the European Association of Urology (EAU) March 18-22 in Vienna, Austria. The accepted abstract is now available to EAU members. Further disclosure of results from this trial will be made during a podium presentation at the annual American Urological Association (AUA) meeting May 14-19 in Washington, D.C.

Phase III Results

The EAU and AUA abstracts highlight results based on an interim analysis of the Phase III trial.  The objective of the trial is to evaluate the efficacy and safety of Urocidin™ in patients with non-muscle-invasive bladder cancer (NMIBC) who are refractory to intravesical BCG therapy and at high risk of progression. A total of 129 patients were enrolled from 25 centers in the U.S. and Canada, with high grade papillary and/or carcinoma in situ (CIS) and having failed to respond to one or more courses of BCG. The overall one-year disease-free survival (DFS) rate was 25 percent. DFS is defined as lack of recurrence or progression to muscle-invasive disease, as confirmed by biopsy.  The one-year DFS rates, when sub-divided by tumor type (e
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. (NYSE ... drug candidates targeting specific pathogens that cause serious infections ... unusual market activity in the Company,s stock, the NYSE ... with its usual practice. The Company stated that its ... About Synthetic Biologics, Inc. Synthetic ...
(Date:7/29/2014)... New high priced hepatitis C drugs will ... projected $2.9 to $5.8 billion next year, according to ... today by the Pharmaceutical Care Management Association (PCMA). Milliman ... as much as 8.6 percent in 2015 as a ... Olysio. The study finds that the majority ...
(Date:7/29/2014)... 29, 2014 According to a ... Navigation Systems Market (Neurosurgical Navigation Systems, ENT Navigation Systems ... Share, Growth, Trends and Forecast, 2014 - 2020", the ... 218.5 million in 2013 and is expected to grow ... to reach an estimated value of USD 295.5 million ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... Oct. 5 The Thompson Group of Companies announced ... (AIT), a Hamilton Sundstrand Corporation business. AIT will ... Group. Financial terms of the purchase were not disclosed. ... manufacture and marketing of process analytical instruments including Analect ...
... CITY, Oct. 5 Orthopedics This Week , a ... Awards for Best New Technology for Spine Care in ... implant and instrument manufacturer focused on unique silicon nitride (SiN) ... in Biomaterials category for its Valeo® AL Lumbar Spacer ...
Cached Medicine Technology:Thompson Group Acquires Hamilton Sundstrand's Applied Instrument Technologies 2Two Amedica®/US Spine® Implant Products Receive Best New Technology Awards from Orthopedics This Week 2
(Date:7/29/2014)... Tampa, Florida (PRWEB) July 29, 2014 More ... Hotel & Casino Tampa will soon be having a complete ... as the place to rock one’s body and soul. , ... salon, which will result in job opportunities for experienced hair ... will be available. Full time team members will be given ...
(Date:7/29/2014)... The Gerontological Society of America (GSA) the ... aging has chosen Corinna E. Lckenhoff, PhD, of ... M. and Paul B. Baltes Foundation Award in Behavioral ... recognizes outstanding early career contributions in behavioral and social ... last ten years are eligible. The award is given ...
(Date:7/29/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... N. Gitlin, PhD, of the Johns Hopkins University Schools ... the M. Powell Lawton Award. , This distinguished ... led to an innovation in gerontological treatment, practice or ... public policy change that has led to some practical ...
(Date:7/29/2014)... Homelands, NY (PRWEB) July 29, 2014 The ... Nation have sent a letter to Washington NFL team owner ... that opposition to the R-word racial slur is emanating from ... the team and Snyder have yet to respond. ... the full text of the letter, which was first ...
(Date:7/29/2014)... 29, 2014 truBrain has created a ... by energy drinks. Think Drinks , available today ... creates optimal conditions for memory, complex reasoning and sustained ... to raise $50,000 over the course of the 30-day ... boost and have compounding effects over time when used ...
Breaking Medicine News(10 mins):Health News:Rock Spa® at Seminole Hard Rock Hotel & Casino Tampa Prepares for Expansion 2Health News:Löckenhoff earns GSA's 2014 Baltes Foundation Award 2Health News:Gitlin earns GSA's 2014 M. Powell Lawton Award 2Health News:Native American Groups Urge Washington Team Owner Dan Snyder to Stop Claiming Name Change Issue Driven by "Elites" Who Are Not People of Color 2Health News:Focus- and Productivity-Enhancing Beverage Launches Crowdfunding Campaign on Indiegogo 2
... a tree affords complete protection from the sun, say researchers ... to sit under a tree and assume that the foliage ... the shade for granted, say researchers at Purdue University in ... reveals just how much protecting from harmful ultraviolet B light ...
... a hormone called Leptin, produced by fat cells, could ... at the University of Hopkins said obese people have ... relationship between obesity and clotting risk is not well ... Dr. Daniel T. Eitzman, a cardiologist and assistant professor ...
... Lyme disease linger despite antibiotic treatment.,Lyme disease, caused by ... very long-lasting fatigue and cognitive problems. Even though antibiotic ... treatment would not be enough to clear up the ... of whom were assigned to the antibiotic ceftriaxone while ...
... should not assume sneezing and watery eyes are always due ... months, you may well assume it's a pollen allergy starting ... or diagnosis might be pollen allergy.// ,Doctors at the ... rhinitis. Here the inner lining of the nose is just ...
... the risk of heart disease. Researchers found that women over ... risk of dying from heart disease. Low levels of certain ... of heart attacks.// ,But the positive impact of taking ... and calcium are part of the standard therapy for the ...
... program can accurately diagnose a heart attack even when some ... of more than 1,000 adults who went to the emergency ... 80% of people who were having a heart attack.// ... to rely on the computer program to diagnose patients with ...
Cached Medicine News:Health News:Computer Program can assist to detect Heart Attack 2
For primary and revision cases...
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Performa cemented stem....
Medicine Products: